A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) versus IV Decitabine in Subjects with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) May 10, 2018 Type of Cancer Leukemia Sponsor Astex Pharmaceuticals Protocol Number ASTX727-02 To Learn More Call (201)-510-0950
